Skip to main content

Whitehawk Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

WHWK$3.22+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I.FINANCIAL INFORMATION2
Item 1.Financial Statements2
Condensed Consolidated Balance Sheets – September 30, 2026 and December 31, 2025 (Unaudited)2
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income –Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)3
Condensed Consolidated Statements of Stockholders’ Equity – Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)4
Condensed Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2026 and 2025 (Unaudited)6
Notes to Condensed Consolidated Financial Statements (Unaudited)7
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations31
Item 3.Quantitative and Qualitative Disclosures About Market Risk42
Item 4.Controls and Procedures43
PART II.OTHER INFORMATION44
Item 1.Legal Proceedings44
Item 1A.Risk Factors44
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds124
Item 3.Defaults Upon Senior Securities124
Item 4.Mine Safety Disclosures124
Item 5.Other Information124
Item 6.Exhibits125
Signatures126

PART I—FINA NCIAL INFORMATION

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.